Kisunla (donanemab-azbt), administered as an intravenous infusion every four weeks, has been approved by the UK regulator to treat mild cognitive impairment and mild dementia due to AD in adults who have one or no copies of the apolipoprotein E4 gene. However, NICE said in draft guidance that the cost of providing the drug means it “cannot currently be considered good value for the taxpayer”, meaning anyone eligible for the drug who wishes to receive it will have to pay for it privately…
